[1] 黄龙, 陈煜, 吴桥, 等. 舒肝宁注射液对于氯丙嗪引起的新型组织工程肝构建的胆汁淤积型药物性肝损伤模型的影响[J]. 临床肝胆病杂志, 2022, 38(3):587-593. [2] Shinozawa T, Kimura M, Cai Y, et al. High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids[J]. Gastroenterology, 2021, 160(3): 831-846. [3] Chalasani NP, Maddur H, Practice Parameters Committee of the American College of Gastroenterology. Acg clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. [4] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. [5] Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: a case series from iceland and the us drug-induced liver injury network[J]. Liver Int, 2020, 40(4): 825-829. [6] Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver injury associated with turmeric-a growing problem: ten cases from the drug-induced liver injury network [dilin][J]. Am J Med, 2023, 136(2): 200-206. [7] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(11): 810-820. [8] 陈茜楠, 徐琰, 刘晓昌, 等. 105例药物性胆汁淤积型肝损伤患者临床特征分析[J]. 安徽医科大学学报, 2023, 58(6):1036-1040. [9] Fang S, Wang T, Li Y, et al. Gardenia jasminoides ellis polysaccharide ameliorates cholestatic liver injury by alleviating gut microbiota dysbiosis and inhibiting the tlr4/nf-κb signaling pathway[J]. Int J Biol Macromol, 2022, 205(1): 23-36. [10] Palmer M, Regev A, Lindor K, et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease[J]. Aliment Pharmacol Ther, 2020, 51(1): 90-109. [11] Sanabria-Cabrera J, Medina-Cáliz I, Stankevičiūté S, et al. Drug-induced liver injury associated with severe cutaneous hypersensitivity reactions: a complex entity in need of a multidisciplinary approach[J]. Curr Pharm Des, 2019, 25(36): 3855-3871. [12] Fu KL, Chen P, Zhou YY, et al. Hepatic vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice[J]. Acta Pharmacol Sin, 2022, 43(4): 933-940. [13] Helal NE, Elkadeem M, Elbastawesy SM, et al. Drug induced liver injury: causative agents and predictors for the outcome-a retrospective study at tanta university hospital, Egypt[J]. Eur Rev Med Pharmacol Sci, 2023, 27(2): 560-569. [14] Xiao Y, Wang Y, Liu Y, et al. A nonbile acid farnesoid x receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis[J]. Liver Int, 2021, 41(9): 2117-2131. [15] Chen J, Wu H, Tang X, et al. 4-phenylbutyrate protects against rifampin-induced liver injury via regulating mrp2 ubiquitination through inhibiting endoplasmic reticulum stress[J]. Bioengineered, 2022, 13(2): 2866-2877. [16] Weber S, Allgeier J, Denk G, et al. Marked increase of gamma-glutamyltransferase as an indicator of drug-induced liver injury in patients without conventional diagnostic criteria of acute liver injury[J]. Visc Med, 2022, 38(3): 223-228. [17] Wu N, Carpino G, Ceci L, et al. Melatonin receptor 1a, but not 1b, knockout decreases biliary damage and liver fibrosis during cholestatic liver injury[J]. Hepatology, 2022, 75(4): 797-813. [18] Zhu W, Wang L, Zhao X, et al. Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug-induced liver injury[J]. Hepatol Res, 2020, 50(2): 224-232. [19] Benitez R, Caro M, Andres-Leon E, et al. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic- and cholestatic-induced liver injury[J]. Br J Pharmacol, 2022, 179(10): 2275-2296. [20] Susukida T, Sekine S, Nozaki M, et al. Prediction of the clinical risk of drug-induced cholestatic liver injury using an in vitro sandwich cultured hepatocyte assay[J]. Drug Metab Dispos, 2015, 43(11):1760-1768.